NTRA · Investment summary · as of 30 July 2026
Priced slightly ahead of what the business has demonstrated
Business type: Inflection · scaling but economically observable
The business does not meet the quality standard for its economic type.
At $269.66, NTRA requires a 47% five-year revenue growth rate to justify its enterprise value — more than the business has ever demonstrated, at 41%.
The value rests on an exit multiple of 14.6x and a terminal operating margin of 23%. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: PAMA/CLFS reset of Signatera reimbursement.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | FY2025 10-K filed 27 February 2026; Q1-2026 10-Q filed 8 May 2026; Q1-2026 8-K Ex-99.1 filed 7 May 2026. |
| What do we forecast? | Revenue growth of 41% demonstrated; a terminal operating margin of 23%; an exit multiple of 14.6x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On revenue growth, the difference between what the price requires and what the business has demonstrated is -6.2 percentage points. |
| What is it worth? | Twelve-month target $276.15, +2% from the struck price. Scenario-weighted expected return net of costs +2.4%. |
| Why now? | Date not announced — no dated event that would resolve the disagreement is on file |
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| any quarterly earnings release, Q2-2026 through Q2-2027 | Total revenues / tests reported | ASP reversal: revenue divided by tests reported falls at or above $700 in any quarter | ASP reversal: revenue divided by tests reported falls below $700 in any quarter |
| FY2026 10-K, expected February 2027 | Loss from operations / total revenues, FY2026 | Neither leg of the condition opposite is met at this date | Guided operating leverage does not arrive: FY2026 GAAP operating margin worse than -9.44% |
| quarterly earnings releases, Q2-2026 through Q2-2027 | Tests reported, YoY growth | Neither leg of the condition opposite is met at this date | Volume growth breaks: tests reported YoY growth below +10% in two consecutive quarters |
| any Natera periodic filing through FY2027 | Company disclosure in a periodic filing | Neither leg of the condition opposite is met at this date | PAMA reset materialises: a Natera 10-Q or 10-K discloses that PAMA private-payer rate reporting has resumed AND that a… |
PAMA/CLFS reset of Signatera reimbursement. Signatera holds CMS Advanced Diagnostic Laboratory Test (ADLT) status. Per the FY2025 10-K, a new ADLT is paid at its actual list charge for three calendar quarters and THEREAFTER at the volume-weighted median of private-payer rates reported under PAMA. PAMA reporting has been suspended since 2021 and is 'delayed, most recently until 2027'; resumption is the trigger.
Estimated probability 20%, against the 30% level at which the position would be resized. It sits within that level.
Falsifiable and fundamental — not one of them is a price condition.
On approach to the $276.15 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Not met | Is the business worth owning under its declared economic type? |
| Valuation | Not determined | Is the operating path required by today's price achievable? Not established on the evidence on file. |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | PAMA/CLFS reset of Signatera reimbursement. |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Not determined | Is there a dated event that resolves the disagreement? Not established on the evidence on file. |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The gap between what today's price requires and what the business has demonstrated is -6.2 percentage points, and that gap — not the multiple — is the case that the security is mispriced. The most important unresolved uncertainty is whether the operating path today's price requires is achievable; the evidence does not settle it. The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $237.25, which forces an immediate review.